1 / 12

How profitable is it to invest in NASH market?

Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase

alliedmarketresearch
Download Presentation

How profitable is it to invest in NASH market?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How profitable is it to invest in NASH market?

  2. 75 Pages Report Published Date : Aug - 2014

  3. Introduction Table of Content Introduction Executive Summary Global 3D Technology Market Overview Global 3D Technology Market by Products Global 3D Technology Market by Applications Global 3D Technology Market by Geography Company Profiles Key Audiences Scope of the Report Key Benefits

  4. Description Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase . Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Global non-alcoholic Steatohepatitis market is expected to garner $1693.2 million by 2020 growing at a CAGR of 25.6% during 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. The market growth is restricted by factors such as NASH’s complex and enigmatic physiological structure and inefficient diagnostics technology; these factors could also prolong the commercialization process for NASH therapeutics.

  5. KEY BENEFITS • Various opportunities for non alcoholic fatty liver disease therapeutics present in developed as well as developing economies are thoroughly assessed • Substitute treatments and their potential impact on NASH therapeutics are strategically quantified in the report • Opportunities from a business perspective latent in the Asia-Pacific region are brought to light • Market dimensions of diagnostic techniques used in NASH monitoring provide a clear outline of the NASH therapeutics research market • Geography-wise segmentation of clinical trials is conducted to provide strategic intelligence to the stakeholder • Pipeline analysis for the key NASH therapeutics under clinical research provides market intelligence needed for commercialization • Detailed analysis of market dynamics provides intelligence about market competencies according to segments • In depth analysis of key players operating in the fatty liver disease therapeutics market is conducted according to regions

  6. Table of Contents Introduction Executive Summary Market Beyond: What To Expect By 2025 Market Overview 5. Global Nonalcoholic Steatohepatitis Market By Drug Types 6. Global Nonalcoholic Steatohepatitis Market 7. Company Profiles

  7. Nonalcoholic Steatohepatitis Market Overview Market Definition Key Findings Impeding opportunities for NASH Other Nonalcoholic Steatohepatitis Market Overview Incongruity about preventative role of Fructose Diagnostic Techniques Prevalence of nonalcoholic fatty liver disease Dos and Don’ts For Nonalcoholic Fatty Liver Disease

  8. Market Dynamics • Market Dynamics Your feedback is important to us What would you like to know more about this Study ? • Global Industry Analysis • Market Size • Market Share • Market Trends • Opportunities and Forecast • Key Market Drivers Market Drivers Rampant rate of obesity and diabetes globally Acceleration in initiatives for research and development activities Market Restraints Blurred understanding of pathophysiology of NASH Please inform us on : http://www.alliedmarketresearch.com/contact-us Inefficient diagnostic technology for NASH Slower development of therapeutics for NASH

  9. Global Nonalcoholic Steatohepatitis Market By Drug Types GFT505 Obeticholic Acid (INT-747) Global Nonalcoholic Steatohepatitis Market By Drug Types Simtuzumab and Liraglutide (Victoza) Vitamin E Poglitazone

  10. Top Market Players of Nonalcoholic Steatohepatitis (NASH) Market  • Genfit. • Gilead Science • Novo Nordisk • Intercepts Pharmaceuticals • Enzo Biochem, Inc. • Raptor Pharmaceutical Corp.

  11. Your feedback is important to us What would you like to know more about this Study ? • Global Industry Analysis • Market Size • Market Share • Market Trends • Opportunities and Forecast Please inform us on : http://www.alliedmarketresearch.com/contact-us

  12. http://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-markethttp://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market

More Related